AR127698A1 - Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno - Google Patents
Derivados de naftiridinona para el tratamiento de una enfermedad o un trastornoInfo
- Publication number
- AR127698A1 AR127698A1 ARP220103160A ARP220103160A AR127698A1 AR 127698 A1 AR127698 A1 AR 127698A1 AR P220103160 A ARP220103160 A AR P220103160A AR P220103160 A ARP220103160 A AR P220103160A AR 127698 A1 AR127698 A1 AR 127698A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- independently selected
- optionally substituted
- substituents independently
- disorder
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 6
- 201000010099 disease Diseases 0.000 title abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 5
- 125000001424 substituent group Chemical group 0.000 abstract 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 102100033063 G protein-activated inward rectifier potassium channel 1 Human genes 0.000 abstract 2
- 101000944266 Homo sapiens G protein-activated inward rectifier potassium channel 1 Proteins 0.000 abstract 2
- 208000006218 bradycardia Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000005764 inhibitory process Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 206010003658 Atrial Fibrillation Diseases 0.000 abstract 1
- 206010003671 Atrioventricular Block Diseases 0.000 abstract 1
- 206010049765 Bradyarrhythmia Diseases 0.000 abstract 1
- 208000016998 Conn syndrome Diseases 0.000 abstract 1
- 208000010271 Heart Block Diseases 0.000 abstract 1
- 208000001953 Hypotension Diseases 0.000 abstract 1
- 229910017711 NHRa Inorganic materials 0.000 abstract 1
- 206010040639 Sick sinus syndrome Diseases 0.000 abstract 1
- 208000004557 Vasovagal Syncope Diseases 0.000 abstract 1
- 206010003119 arrhythmia Diseases 0.000 abstract 1
- 230000036471 bradycardia Effects 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 230000037417 hyperactivation Effects 0.000 abstract 1
- 230000036543 hypotension Effects 0.000 abstract 1
- 230000001734 parasympathetic effect Effects 0.000 abstract 1
- 208000013846 primary aldosteronism Diseases 0.000 abstract 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Abstract
Reivindicación 1: Un compuesto de la fórmula (1) o una de sus sales farmacéuticamente aceptables, donde R¹ es (C₁-C₆)alquilo sustituido con uno o más sustituyentes seleccionados de manera independiente de -OH, -C(O)NHRᵃ y un heterociclo de 4 a 6 miembros que está opcionalmente sustituido con uno o más -OH; A es -OR² o (C₁-C₆)alquilo opcionalmente sustituido con uno o más sustituyentes seleccionados de manera independiente de -SO₂(C₁-C₄)alquilo, -NHC(O)Rᵇ, y -C(O)NHRᶜ; R² es (C₁-C₆)alquilo sustituido con uno o más sustituyentes seleccionados de manera independiente de -NHC(O)Rᵈ y -C(O)NHRᵉ, donde el (C₁-C₆)alquilo está además opcionalmente sustituido con uno o más sustituyentes seleccionados de manera independiente de halo, -OH y -CN; Rᵃ, Rᵇ, Rᶜ, Rᵈ, y Rᵉ están cada uno seleccionados de manera independiente de H y (C₁-C₆)alquilo opcionalmente sustituido con uno o más -OH; y R³ es (C₁-C₄)alquilo. Reivindicación 15: Un compuesto de acuerdo con cualquiera de las reivindicaciones 1 a 10 o una de sus sales farmacéuticamente aceptables, para el uso en el tratamiento de una enfermedad o un trastorno que responde a la inhibición del receptor GIRK1/4, donde la enfermedad o el trastorno que responde a la inhibición del receptor GIRK1/4 se selecciona de arritmia cardíaca, fibrilación auricular, bradiarritmia, bradicardia, bloqueo cardíaco, síndrome del seno enfermo, hiperactivación parasimpática, hiperaldosteronismo primario, hipotensión, y síncope vasovagal.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163282492P | 2021-11-23 | 2021-11-23 | |
| CN2022128601 | 2022-10-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR127698A1 true AR127698A1 (es) | 2024-02-21 |
Family
ID=84370237
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220103160A AR127698A1 (es) | 2021-11-23 | 2022-11-16 | Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20230203032A1 (es) |
| AR (1) | AR127698A1 (es) |
| TW (1) | TW202329949A (es) |
| WO (1) | WO2023094965A1 (es) |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5118666A (en) | 1986-05-05 | 1992-06-02 | The General Hospital Corporation | Insulinotropic hormone |
| US5120712A (en) | 1986-05-05 | 1992-06-09 | The General Hospital Corporation | Insulinotropic hormone |
| ES2113879T3 (es) | 1990-01-24 | 1998-05-16 | Douglas I Buckley | Analogos de glp-1 utiles para el tratamiento de diabetes. |
| EP0618803A4 (en) | 1991-12-19 | 1995-03-22 | Southwest Found Biomed Res | POLYPEPTIDE INHIBITING PROTEIN TRANSFER TO CHOLESTERYL ESTERS, ANTIBODIES AGAINST SYNTHETIC POLYPEPTIDE AND ANTI-ATHEROSCLEROSIS PROPHYLACTIC AND THERAPEUTIC TREATMENTS. |
| IL111785A0 (en) | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
| US5705483A (en) | 1993-12-09 | 1998-01-06 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
| US5512549A (en) | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
| DE122010000020I1 (de) | 1996-04-25 | 2010-07-08 | Prosidion Ltd | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
| TW492957B (en) | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
| US6197786B1 (en) | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
| GT199900147A (es) | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
| CO5150173A1 (es) | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
| US6677341B2 (en) | 1999-09-23 | 2004-01-13 | Pharmacia Corporation | (R)-Chiral halogenated substituted heteroaryl benzyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity |
| PL358459A1 (en) | 2000-04-12 | 2004-08-09 | Novartis Ag | Novel medical use of aldosterone synthase inhibitors alone or in combination with at1-receptor antagonists |
| ES2270143T3 (es) | 2002-08-07 | 2007-04-01 | Novartis Ag | Compuestos organicos como agentes para el tratamiento de condiciones mediadas por aldosterona. |
| US7223866B2 (en) | 2002-11-18 | 2007-05-29 | Novartis Ag | Imidazo[1,5-a]pyridine derivatives and methods for treating aldosterone mediated diseases |
| JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
| BRPI0508966A (pt) | 2004-03-26 | 2007-08-21 | Lilly Co Eli | composto, composição farmacêutica, e, uso de um composto |
| UA90269C2 (ru) | 2004-04-02 | 2010-04-26 | Мицубиси Танабе Фарма Корпорейшн | Тетрагидрохинолиновые производные и способ их получения |
| JP2008500999A (ja) | 2004-05-28 | 2008-01-17 | シュペーデル・エクスペリメンタ・アーゲー | 複素環式化合物およびアルドステロンシンターゼ阻害薬としてのそれらの使用 |
| CA2568165A1 (en) | 2004-05-28 | 2005-12-15 | Speedel Experimenta Ag | Heterocyclic compounds and their use as aldosterone synthase inhibitors |
| CN1960991A (zh) | 2004-05-28 | 2007-05-09 | 斯皮德尔实验股份公司 | 用作醛固酮合酶抑制剂的四氢咪唑并[1,5－a]吡啶衍生物 |
| WO2006005726A2 (en) | 2004-07-09 | 2006-01-19 | Speedel Experimenta Ag | Heterocyclic compounds |
| TW200716636A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
| TW200716634A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
| TW200716105A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Imidazole compounds |
| GT200600381A (es) | 2005-08-25 | 2007-03-28 | Compuestos organicos | |
| AR056888A1 (es) | 2005-12-09 | 2007-10-31 | Speedel Experimenta Ag | Derivados de heterociclil imidazol |
| US20090156875A1 (en) | 2006-04-04 | 2009-06-18 | Takafumi Tomioka | Methane separation method, methane separation apparatus, and methane utilization system |
| TW200808812A (en) | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
| TW200808813A (en) | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
| EP1886695A1 (en) | 2006-06-27 | 2008-02-13 | Speedel Experimenta AG | Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist |
| RU2009110442A (ru) | 2006-08-25 | 2010-09-27 | Новартис АГ (CH) | Конденсированные производные имидазола для лечения нарушений, опосредованных альдостеронсинтазой, и/или 11-бета-гидроксилазой, и/или ароматазой |
| CN101578272A (zh) | 2006-12-18 | 2009-11-11 | 诺瓦提斯公司 | 1-取代的咪唑衍生物和它们作为醛固酮合酶抑制剂的用途 |
| JP2010513558A (ja) | 2006-12-18 | 2010-04-30 | ノバルティス アーゲー | ４−イミダゾリル−１，２，３，４−テトラヒドロキノリン誘導体、およびアルドステロン／１１−ベータ−ヒドロキシラーゼ阻害剤としてのその使用 |
| CA2672269A1 (en) | 2006-12-18 | 2008-06-26 | Novartis Ag | Organic compounds |
| ATE484507T1 (de) | 2007-03-29 | 2010-10-15 | Novartis Ag | Heterocyclische spiroverbindungen |
| NZ627942A (en) | 2012-01-27 | 2016-03-31 | Gilead Sciences Inc | Combination therapies using late sodium ion channel blockers and potassium ion channel blockers |
| JOP20190086A1 (ar) * | 2016-10-21 | 2019-04-18 | Novartis Ag | مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب |
| EP3801504A4 (en) * | 2018-06-11 | 2022-07-27 | Northeastern University | SELECTIVE LIGANDS FOR MODULATION OF GIRK CHANNELS |
-
2022
- 2022-11-16 AR ARP220103160A patent/AR127698A1/es unknown
- 2022-11-21 TW TW111144406A patent/TW202329949A/zh unknown
- 2022-11-21 US US18/057,505 patent/US20230203032A1/en active Pending
- 2022-11-21 WO PCT/IB2022/061218 patent/WO2023094965A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| US20230203032A1 (en) | 2023-06-29 |
| WO2023094965A1 (en) | 2023-06-01 |
| TW202329949A (zh) | 2023-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2551557T3 (es) | Pirimidin-4-carboxamidas cíclicas como antagonistas del receptor CCR2 para el tratamiento de inflamaciones, asma y EPOC | |
| AR086983A1 (es) | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak | |
| PE20212253A1 (es) | Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatia dilatada (mcd) | |
| AR117617A1 (es) | Compuestos de sulfonilurea como inhibidores de la actividad de interleuquina 1 | |
| AR057322A1 (es) | Quinazolinonas, procesos de obtencion y composiciones farmaceuticas | |
| AR110753A1 (es) | Inhibidores selectivos de jak1 | |
| AR110789A1 (es) | Compuestos moduladores del receptor de hidrocarburos de arilo (ahr) | |
| AR110790A1 (es) | Compuestos moduladores del receptor de hidrocarburos de arilo (ahr) | |
| JP2020500869A5 (es) | ||
| AR120029A1 (es) | Compuestos heterocíclicos | |
| EA201990902A1 (ru) | Ингибиторы тирозинкиназы брутона | |
| AR078536A1 (es) | Derivados de pirazol como ligandos del receptor de estrogeno | |
| AR088258A1 (es) | Inhibidores de la pde10 de azetidina 1,3-sustituida | |
| WO2017072341A1 (en) | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease | |
| AR121777A1 (es) | Derivados de diamina macrocíclica como inhibidores de ent para el tratamiento de cánceres, y combinación de estos con antagonistas del receptor de adenosina | |
| AR089944A1 (es) | Derivados de tetrahidro-quinazolinona | |
| AR104963A1 (es) | Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak | |
| RS52034B (en) | ANTITUMOR DIHIDROPYRANE-2-ON UNITS | |
| AR092749A1 (es) | Compuestos farmaceuticos | |
| PE20181017A1 (es) | Compuestos heteroarilo y su uso como farmacos terapeuticos | |
| CO2018002516A2 (es) | Derivados de n-(4-cloro-3(hidroxi-1,3,5-triazin-2-il)bencil)-carboxamida, activos como inhibidores de prostaglandina microsomal e2 sintasa-1 (mpegs-1), composiciones de los mismos y métodos de preparación de los mismos | |
| WO2017109088A1 (en) | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease | |
| AR127698A1 (es) | Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno | |
| AR109108A1 (es) | Derivados de aminopiridina y su uso como inhibidores selectivos de alk-2 | |
| AR119728A1 (es) | Derivados de 1,1-dioxido de 3-amino-4h-benzo[e][1,2,4]tiadiazina como inhibidores de mrgx2 |